Citations 221

S4‐02‐04: Accelerating Medicines Partnership: Identifying Therapeutic Targets for Alzheimer's Disease with Comparative Transcriptomics

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_6 | Pages: No page available

10.1016/j.jalz.2016.06.587

P1‐117: Blood Gene Expression Changes Implicated in Alzheimer’s Disease

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_9 | Pages: No page available

10.1016/j.jalz.2016.06.865

O2‐06‐02: Genome‐Wide Meta‐Analysis of Transcriptome Profiling Identifies Novel Dysregulated Genes Implicated in Alzheimer's Disease

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_5 | Pages: No page available

10.1016/j.jalz.2016.06.425

P4‐031: Integrative Network Analysis of Multiple Alzheimer's Disease Rnaseq Studies From the Accelerating Medicine Partnership‐Alzheimer's Disease Consortium

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_21 | Pages: No page available

10.1016/j.jalz.2016.06.2120

P3‐092: Mapping Regulatory Variants in the Alzheimer's Disease Candidate Gene ABCA7

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_17 | Pages: No page available

10.1016/j.jalz.2016.06.1751

P2‐079: Assessment of The Known and Candidate Alzheimer's Disease Genes in African‐Americans

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_13 | Pages: No page available

10.1016/j.jalz.2016.06.1284

P4‐027: Combing Evidence Across Multiple Cohorts for Systems‐Based Target Discovery: the AMP‐AD Knowledge Portal

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_21 | Pages: No page available

10.1016/j.jalz.2016.06.2116

TREM2 p.R47H substitution is not associated with dementia with Lewy bodies

Neurology Genetics | July 15, 2016 | Volume: 2 | Issue: 4 | Pages: No page available

10.1212/nxg.0000000000000085 | PMID 27458607

MAPT haplotype H1G is associated with increased risk of dementia with Lewy bodies

Alzheimer's & Dementia | June 8, 2016 | Volume: 12 | Issue: 12 | Pages: 1297-1304

10.1016/j.jalz.2016.05.002 | PMID 27287057

Abstract Introduction The MAPT H1 haplotype has been associated with several neurodegenerative diseases. We were interested in exploring the role of MAPT haplotypic variation in risk of dementia with Lewy bodies (DLB). Method We genotyped six MAPT haplotype tagging SNPs and screened 431 clinical DLB cases, 347 pathologically defined high‐likelihood DLB cases, and 1049 controls. Result We performed haplotypic association tests and detected an association with the protective H2 haplotype in our combined series (odds ratio [OR] = 0.75). We fine‐mapped the locus and identified a relatively rare haplotype, H1G, that is associated with an increased risk of DLB (OR = 3.30, P = .0017). This association was replicated in our pathologically defined series (OR = 2.26, P = .035). Discussion These results support a role for H1 and specifically H1G in susceptibility to DLB. However, the exact functional variant at the locus is still unknown, and additional studies are warranted to fully explain genetic risk of DLB at the MAPT locus.
Genetic risk factors for the posterior cortical atrophy variant of Alzheimer's disease

Alzheimer's & Dementia | March 15, 2016 | Volume: 12 | Issue: 8 | Pages: 862-871

10.1016/j.jalz.2016.01.010 | PMID 26993346

AbstractIntroductionThe genetics underlying posterior cortical atrophy (PCA), typically a rare variant of Alzheimer's disease (AD), remain uncertain.MethodsWe genotyped 302 PCA patients from 11 centers, calculated risk at 24 loci for AD/DLB and performed an exploratory genome‐wide association study.ResultsWe confirm that variation in/near APOE/TOMM40 (P = 6 × 10−14) alters PCA risk, but with smaller effect than for typical AD (PCA: odds ratio [OR] = 2.03, typical AD: OR = 2.83, P = .0007). We found evidence for risk in/near CR1 (P = 7 × 10−4), ABCA7 (P = .02) and BIN1 (P = .04). ORs at variants near INPP5D and NME8 did not overlap between PCA and typical AD. Exploratory genome‐wide association studies confirmed APOE and identified three novel loci: rs76854344 near CNTNAP5 (P = 8 × 10−10 OR = 1.9 [1.5–2.3]); rs72907046 near FAM46A (P = 1 × 10−9 OR = 3.2 [2.1–4.9]); and rs2525776 near SEMA3C (P = 1 × 10−8, OR = 3.3 [2.1–5.1]).DiscussionWe provide evidence for genetic risk factors specifically related to PCA. We identify three candidate loci that, if replicated, may provide insights into selective vulnerability and phenotypic diversity in AD.